Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217646 | 0.74 | ADRB2 (0.44) | ADRB2ADRB1ADRB3 | |
| SCHEMBL9436624 | 0.74 | ADRB2 (0.44) | ADRB2ADRB1ADRB3 | |
| SCHEMBL16217648 | 0.73 | ADRB2 (0.43) | ADRB2ADRB1ADRB3 | |
| SCHEMBL812981 | 0.71 | ADRB2 (0.44) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2160941 | 0.70 | ADRB2 (0.34) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2161806 | 0.65 | ADRB2 (0.41) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2161774 | 0.65 | ADRB2 (0.38) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2161830 | 0.64 | ADRB2 (0.40) | ADRB2ADRB1ADRB3 | |
| SCHEMBL13072978 | 0.64 | ACACB (0.41) | — | |
| SCHEMBL13258901 | 0.64 | ACACB (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217698-B2 | Use of mannosamine derivatives for the stimulation of neurite growth | DOMPATENT VON KREISLER SELTING WERNER (DE) | 2007-05-15 | — | — | US | disclosed |
| US-20050107333-A1 | Use of mannosamine derivatives for the stimulation of neurite growth | REUTTER WERNER (DE) | 2005-05-19 | — | — | US | disclosed |
| EP-1429788-A2 | USE OF MANNOSAMINE DERIVATIVES FOR THE STIMULATION OF NEURITE GROWTH | Reutter, Werner (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003028709-A2 | USE OF MANNOSAMINE DERIVATIVES FOR THE STIMULATION OF NEURITE GROWTH | REUTTER WERNER (DE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107333-A1 | Use of mannosamine derivatives for the stimulation of neurite growth | NGF, BDNF, GAP43 | ADRB2 1896/4885ADRB1 2383/4885ADRB3 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.